Resistance to rapamycin: A novel anticancer drug

Shile Huang; Peter J. Houghton

doi:10.1023/A:1013167315885

Resistance to rapamycin: A novel anticancer drug

Shile Huang, Peter J. Houghton

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.

Original language	English (US)
Pages (from-to)	69-78
Number of pages	10
Journal	Cancer and Metastasis Reviews
Volume	20
Issue number	1-2
DOIs	https://doi.org/10.1023/A:1013167315885
State	Published - 2001
Externally published	Yes

Keywords

Apoptosis
Cancer
Cell cycle
Cell proliferation
Rapamycin
Resistance

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1023/A:1013167315885

Cite this

@article{d61d08e46d324721866cd5991a5d67c0,

title = "Resistance to rapamycin: A novel anticancer drug",

abstract = "The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.",

keywords = "Apoptosis, Cancer, Cell cycle, Cell proliferation, Rapamycin, Resistance",

author = "Shile Huang and Houghton, {Peter J.}",

note = "Funding Information: This work is supported in part by USPHS awards CA77776, CA23099, and CA28765 (Cancer Center Support Grant) from the National Cancer Institute, through a grant from Wyeth-Ayerst Company, and American, Lebanese, Syrian Associated Charities (ALSAC).",

year = "2001",

doi = "10.1023/A:1013167315885",

language = "English (US)",

volume = "20",

pages = "69--78",

journal = "Cancer and Metastasis Reviews",

issn = "0167-7659",

publisher = "Springer Netherlands",

number = "1-2",

}

TY - JOUR

T1 - Resistance to rapamycin

T2 - A novel anticancer drug

AU - Huang, Shile

AU - Houghton, Peter J.

N1 - Funding Information: This work is supported in part by USPHS awards CA77776, CA23099, and CA28765 (Cancer Center Support Grant) from the National Cancer Institute, through a grant from Wyeth-Ayerst Company, and American, Lebanese, Syrian Associated Charities (ALSAC).

PY - 2001

Y1 - 2001

N2 - The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.

AB - The macrocyclic lactone rapamycin has an established place as an immune suppressive agent in organ transplantation. However, more recently it has been recognized as an inhibitor of pathways that may be activated during malignant transformation and tumor progression. Thus, increasing interest is being directed to this class of antibiotic as potential antitumor agents. Here we summarize the history, mechanism of action, and mechanisms of resistance to rapamycin.

KW - Apoptosis

KW - Cancer

KW - Cell cycle

KW - Cell proliferation

KW - Rapamycin

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=0035694808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035694808&partnerID=8YFLogxK

U2 - 10.1023/A:1013167315885

DO - 10.1023/A:1013167315885

M3 - Article

C2 - 11831650

AN - SCOPUS:0035694808

VL - 20

SP - 69

EP - 78

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

SN - 0167-7659

IS - 1-2

ER -

Resistance to rapamycin: A novel anticancer drug

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this